Tea Štimac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tea Štimac has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Ana-Maria Šopić Rahelić
Department of Obstetrics and Gynecology, Clinical Hospital Center and University of Rijeka, Cambierieva 17/V, 51000 Rijeka, Croatia
1 shared publication- Andrea Dekanić
Department of Pathology and Cytology, Clinical Hospital Center Rijeka, Rijeka, Croatia.
1 shared publication Eduard Eškinja
Department of Obstetrics and Gynecology, Clinical Hospital Center and University of Rijeka, Cambierieva 17/V, 51000 Rijeka, Croatia
1 shared publication- Ena Holjević
Department of Pathology and Cytology, Clinical Hospital Centre Rijeka, Krešimirova ulica 42, 51000 Rijeka, Croatia
1 shared publication Isaac Blickstein
Department of Obstetrics and Gynecology, Kaplan Medical Center, Rehovot, Affiliated with the Hadassah-Hebrew University School of Medicine, Jerusalem, Israel
1 shared publicationJelena Ivandić
Department of Obstetrics and Gynecology, Clinical Hospital Center and University of Rijeka, Cambierieva 17/V, 51000 Rijeka, Croatia
1 shared publication
Latest Publications
- Open Access
- 27 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1576
Survivin Expression in Placentas with Intrauterine Growth Restriction
Background/Objectives: Intrauterine growth restriction (IUGR) is a pathological condition defined by a reduced fetal ability to achieve the genetically expected growth potential during gestation. It affects 5–10% of all pregnancies and it is a leading cause of perinatal morbidity and mortality. During the initial phases of placentation, complex interlinked processes including cell proliferation, differentiation, apoptosis and the invasion of trophoblasts occur. Alterations in the regulation of these processes lead to placental dysfunction. Survivin, a member of the inhibitor of apoptosis (IAP) family, plays an important role in cell proliferation balance and apoptosis, thus leading to proper placental development. This study aimed to evaluate survivin expression in placentas from IUGR and healthy pregnancies to explore its potential as a biomarker for the early diagnosis, prevention, and treatment of IUGR. Methods: Survivin presence was determined in 153 archival formalin-fixed and paraffin-embedded placental tissues from IUGR (N = 122) and uncomplicated (N = 31) term pregnancies. Tissue microarrays (TMAs) were constructed, and survivin expression was assessed using immunohistochemistry (IHC). Survivin levels were quantified using positive cell proportion (PCP) scores and immunoreactive scores (IRS), with statistical significance determined using mean values, standard deviation (SD), standard error, and Student’s t test in instances of normal distribution, and when this was not the case, the Mann–Whitney test. Chi-square tests, Fisher exact tests, and t-tests (p < 0.05) were used to compare categorical variables. Results: Our results suggested the significantly higher expression of survivin validated with PCP (p < 0.001) and IRS (p < 0.002) in placentas with IUGR compared to placentas from non-complicated term pregnancies. Conclusions: Increased survivin expression in IUGR placentas points to its potential role as a key indicator of placental dysfunction. By signaling early pathological changes, survivin may offer a valuable tool for the early detection of IUGR, potentially allowing for timely clinical interventions that could reduce the risk of serious outcomes, including stillbirth. To fully establish survivin’s clinical value, further research is needed to validate its diagnostic accuracy and to explore its involvement in molecular pathways that may be targeted for therapeutic benefit.
- 27 June 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1576
Open AccessSurvivin Expression in Placentas with Intrauterine Growth Restriction
Background/Objectives: Intrauterine growth restriction (IUGR) is a pathological condition defined by a reduced fetal ability to achieve the genetically expected growth potential during gestation. It affects 5–10% of all pregnancies and it is a leading cause of perinatal morbidity and mortality. During the initial phases of placentation, complex interlinked processes including cell proliferation, differentiation, apoptosis and the invasion of trophoblasts occur. Alterations in the regulation of these processes lead to placental dysfunction. Survivin, a member of the inhibitor of apoptosis (IAP) family, plays an important role in cell proliferation balance and apoptosis, thus leading to proper placental development. This study aimed to evaluate survivin expression in placentas from IUGR and healthy pregnancies to explore its potential as a biomarker for the early diagnosis, prevention, and treatment of IUGR. Methods: Survivin presence was determined in 153 archival formalin-fixed and paraffin-embedded placental tissues from IUGR (N = 122) and uncomplicated (N = 31) term pregnancies. Tissue microarrays (TMAs) were constructed, and survivin expression was assessed using immunohistochemistry (IHC). Survivin levels were quantified using positive cell proportion (PCP) scores and immunoreactive scores (IRS), with statistical significance determined using mean values, standard deviation (SD), standard error, and Student’s t test in instances of normal distribution, and when this was not the case, the Mann–Whitney test. Chi-square tests, Fisher exact tests, and t-tests (p < 0.05) were used to compare categorical variables. Results: Our results suggested the significantly higher expression of survivin validated with PCP (p < 0.001) and IRS (p < 0.002) in placentas with IUGR compared to placentas from non-complicated term pregnancies. Conclusions: Increased survivin expression in IUGR placentas points to its potential role as a key indicator of placental dysfunction. By signaling early pathological changes, survivin may offer a valuable tool for the early detection of IUGR, potentially allowing for timely clinical interventions that could reduce the risk of serious outcomes, including stillbirth. To fully establish survivin’s clinical value, further research is needed to validate its diagnostic accuracy and to explore its involvement in molecular pathways that may be targeted for therapeutic benefit.
- 28 April 2020
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 48 (4) , 411-415
The contribution of twins conceived by in vitro fertilization to preterm birth rate: observations from a quarter of century
Objective Little information exists related to the contribution of assisted reproductive technology (ART) twins to the preterm and very preterm birth rate. We sought to examine this contribution over a period of more than two decades in a tertiary perinatal center. Methods We identified all preterm births from 1993 to 2017, born at 2 = 0.6). We demonstrated an increase in IVF twin births at <37 weeks but not for spontaneously conceived twins. Whereas the twin birth rate at <32 weeks did not change over time, all preterm births at <32 weeks following IVF were twins. Conclusion The risk of twins after ART increasingly contributes to preterm births at <37 weeks and ART twins are at significant risk for preterm births at <32 weeks.
- 28 April 2020
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 48 (4) , 411-415
The contribution of twins conceived by in vitro fertilization to preterm birth rate: observations from a quarter of century
Objective Little information exists related to the contribution of assisted reproductive technology (ART) twins to the preterm and very preterm birth rate. We sought to examine this contribution over a period of more than two decades in a tertiary perinatal center. Methods We identified all preterm births from 1993 to 2017, born at 2 = 0.6). We demonstrated an increase in IVF twin births at <37 weeks but not for spontaneously conceived twins. Whereas the twin birth rate at <32 weeks did not change over time, all preterm births at <32 weeks following IVF were twins. Conclusion The risk of twins after ART increasingly contributes to preterm births at <37 weeks and ART twins are at significant risk for preterm births at <32 weeks.
- Open Access
- 1 December 2017
- Published by University of Rijeka, Faculty of Medicine in Medicina Fluminensis
- Vol. 53 (4) , 489-494
Medicina temeljena na dokazima: pogled ginekologa i opstetričara
Koncept medicine utemeljene na dokazima je u proteklih dvadesetak godina postao prepoznatljiv među kliničarima mnogih specijalnosti uključujući ginekologe i porodničare. Medicina utemeljena na dokazima je sveprisutna u medicini,...
- 1 December 2017
- Published by University of Rijeka, Faculty of Medicine in Medicina Fluminensis
- Vol. 53 (4) , 489-494
Open AccessMedicina temeljena na dokazima: pogled ginekologa i opstetričara
Koncept medicine utemeljene na dokazima je u proteklih dvadesetak godina postao prepoznatljiv među kliničarima mnogih specijalnosti uključujući ginekologe i porodničare. Medicina utemeljena na dokazima je sveprisutna u medicini,...